Wall Street Zen Downgrades CME Group (NASDAQ:CME) to Sell

Key Points

• Wall Street Zen downgraded CME Group (NASDAQ:CME) from a "hold" to a "sell," though the MarketBeat consensus remains a Moderate Buy with a $306.71 consensus target (analyst mix: 2 Strong Buy, 8 Buy, 6 Hold, 2 Sell).
• CME beat Q1 expectations with EPS of $3.36 (vs. $3.11 est.) and revenue of $1.88B (vs. $1.77B), reporting record Q1 revenue and trading volumes, but several analysts trimmed price targets and market reaction was mixed.
• Insiders have been selling recently (e.g., General Counsel sold 3,291 shares at about $333.37) while institutional investors own roughly 87.8% of the stock.

CME Group (NASDAQ:CME - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday.

Other analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of CME Group from $342.00 to $322.00 and set a "buy" rating for the company in a research note on Thursday. UBS Group reiterated a "neutral" rating and issued a $310.00 price objective on shares of CME Group in a research note on Friday, February 6th. Rothschild & Co Redburn lowered their price objective on shares of CME Group from $347.00 to $340.00 and set a "neutral" rating for the company in a research note on Monday, April 13th. JPMorgan Chase & Co. lifted their price objective on shares of CME Group from $266.00 to $271.00 and gave the company an "underweight" rating in a research note on Thursday, April 16th. Finally, Argus reiterated a "hold" rating on shares of CME Group in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $306.71.

CME Group Stock Down 0.2%

CME Group stock opened at $285.02 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.03 and a current ratio of 1.02. CME Group has a 52-week low of $257.17 and a 52-week high of $329.16. The firm has a 50 day moving average price of $304.51 and a two-hundred day moving average price of $286.23. The firm has a market cap of $102.22 billion, a price-to-earnings ratio of 24.32, a PEG ratio of 3.02 and a beta of 0.26.

CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The financial services provider reported $3.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.25. The firm had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.77 billion. CME Group had a net margin of 63.19% and a return on equity of 15.42%. The company's revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.80 EPS. Equities analysts predict that CME Group will post 12.26 EPS for the current year.

Insider Buying and Selling at CME Group

In related news, General Counsel Jonathan L. Marcus sold 3,291 shares of CME Group stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $333.37, for a total value of $1,097,120.67. Following the completion of the sale, the general counsel owned 7,192 shares of the company's stock, valued at approximately $2,397,597.04. This trade represents a 31.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Martin J. Gepsman sold 300 shares of CME Group stock in a transaction on Friday, February 20th. The shares were sold at an average price of $305.90, for a total transaction of $91,770.00. Following the completion of the sale, the director directly owned 24,999 shares of the company's stock, valued at approximately $7,647,194.10. The trade was a 1.19% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 8,539 shares of company stock worth $2,713,821. 0.30% of the stock is owned by company insiders.

Institutional Trading of CME Group

Several hedge funds have recently bought and sold shares of the business. Boston Trust Walden Corp grew its position in CME Group by 4.9% in the 1st quarter. Boston Trust Walden Corp now owns 15,151 shares of the financial services provider's stock valued at $4,475,000 after purchasing an additional 702 shares during the period. Center for Wealth Management Advisory grew its position in CME Group by 2.0% in the 1st quarter. Center for Wealth Management Advisory now owns 5,920 shares of the financial services provider's stock valued at $1,749,000 after purchasing an additional 115 shares during the period. Root Financial Partners LLC grew its position in CME Group by 13.2% in the 1st quarter. Root Financial Partners LLC now owns 394 shares of the financial services provider's stock valued at $116,000 after purchasing an additional 46 shares during the period. CHICAGO TRUST Co NA grew its position in CME Group by 9.2% in the 1st quarter. CHICAGO TRUST Co NA now owns 2,423 shares of the financial services provider's stock valued at $716,000 after purchasing an additional 205 shares during the period. Finally, Trust Investment Advisors acquired a new stake in CME Group in the 1st quarter valued at $1,014,000. Institutional investors and hedge funds own 87.75% of the company's stock.

Key Stories Impacting CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record Q1 revenue and volumes: CME reported record Q1 revenue and a surge in trading volumes, driven by higher hedging and risk-management activity — a core driver of futures and options trading revenue. Article Title
• Positive Sentiment: Earnings-call commentary backs the volume story: Management emphasized broad-based demand and rising market risk that is increasing hedging flows — a positive outlook for transaction-driven revenue. Article Title Article Title
• Positive Sentiment: Full earnings transcript available for deeper color: Investors can review management's detail on volume drivers and segment performance. Article Title
• Neutral Sentiment: Multiple analysts trimmed price targets but kept constructive ratings: Deutsche Bank cut its PT to $322 (keeps buy) and TD Cowen cut to $323 (keeps buy); Morgan Stanley trimmed to $353 but retained overweight — these lower targets reflect model updates despite continued positive ratings. Article Title Article Title Article Title
• Neutral Sentiment: No meaningful short-interest signal: the short-interest data published for April is effectively zero/unchanged and does not explain the move. (No linked article.)
• Negative Sentiment: Goldman maintains a sell rating and lowered its PT to $267 — the most bearish big-bank view in the group and a direct negative for sentiment. Article Title
• Negative Sentiment: Mixed market reaction and some headline takes that Q1 sales missed analyst expectations or that the stock looks expensive post-earnings — these narratives can pressure short-term price action despite strong volume trends. Article Title Article Title

About CME Group

CME Group Inc is a global markets company that operates some of the world's largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company's core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.